2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. RET

RET

RET

Related Products

PDF 0.67 MB

RET (REarranged during Transfection) is a transmembrane receptor tyrosine kinase that is activated by a complex consisting of a soluble glial cell line-derived neurotrophic factor (GDNF) family ligand (GFL) and a glycosyl phosphatidylinositol-anchored co-receptor, GDNF family receptors alpha (GFRalpha).

RET signalling is crucial for the development of the enteric nervous system. RET regulates the development of sympathetic, parasympathetic, motor, and sensory neurons, and is necessary for the postnatal maintenance of dopaminergic neurons. RET also plays a role as a driver oncogene in a variety of human cancers. Fusion of RET with several partner genes has been detected in papillary thyroid, lung, colorectal, pancreatic, and breast cancers, and tyrosine kinase inhibitors (TKIs) for RET (particularly RET-specific inhibitors) show promising effects against such cancers.

RET Related Products (140):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-143615
    RET-IN-10
    		Inhibitor
    RET-IN-10 is a potent inhibitor of RET. RET loss of function mutations leads to Hirschsprung's disease, while its gain of function mutations is associated with a variety of human tumors. RET-IN-10 has the potential for the research of cancer diseases (extracted from patent WO2021135938A1, compound 18).
    RET-IN-10
  • HY-E70766
    RET E762Q Recombinant Human Active Protein Kinase
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET E762Q is a mutant of RET. RET E762Q Recombinant Human Active Protein Kinase is a recombinant RET E762Q protein that can be used to study RET E762Q-related functions.
    RET E762Q Recombinant Human Active Protein Kinase
  • HY-151945
    TRK II-IN-1
    		Inhibitor
    TRK II-IN-1 is a potent type II TRK inhibitor, with IC50s of 3.3, 6.4, 4.3 and 9.4 nM, for TRKA/B/C and TRKAG667C, respectively. TRK II-IN-1 also inhibits FLT3, RET, and VEGFR2 with IC50s of 1.3, 9.9, and 71.1 nM, respectively. TRK II-IN-1 can be used for the research of TRK driven cancers.
    TRK II-IN-1
  • HY-144131
    RET-IN-11
    		Inhibitor
    RET-IN-11 is a potent and selective RET inhibitor with IC50s of 6.20 nM, 18.68 nM for RET and RETV804M, respectively. RET-IN-11 shows anti-proliferation and migration activity in CCDC6-RET-driven LC-2/ad cells. RET-IN-11 induces cell apoptosis.
    RET-IN-11
  • HY-148015
    Enbezotinib (enantiomer)
    		Inhibitor 99.72%
    Enbezotinib (enantiomer) (Compound 44) is the enantiomer form of Enbezotinib (HY-145565). Enbezotinib is an inhibitor of RET.
    Enbezotinib (enantiomer)
  • HY-168868
    RET ligand-2
    		Inhibitor
    RET ligand-2 is a selective RET inhibitor. RET ligand-2 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC RET degraders with antitumor activity. RET ligand-2 can be used for the synthesis of RD-23 (HY-168867).
    RET ligand-2
  • HY-18507A
    AD57 hydrochloride
    		Inhibitor
    AD57 hydrochloride is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src.
    AD57 hydrochloride
  • HY-E70780
    RET Y791F Recombinant Human Active Protein Kinase
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET Y791F is a mutant of RET. RET Y791F Recombinant Human Active Protein Kinase is a recombinant RET Y791F protein that can be used to study RET Y791F-related functions.
    RET Y791F Recombinant Human Active Protein Kinase
  • HY-176884
    CDD-2110
    		Inhibitor
    CDD-2210 is a STK33 inhibitor, with a Kd of 0.1 nM and an IC50 of 38 nM. CDD-2210 has relatively weak inhibitory effects on off-target kinases, with IC50 values of 1209 nM for CLK1, 917 nM for CLK2, 544 nM for CLK4, and 746 nM for RET. CDD-2210 can be used for the study of contraception.
    CDD-2110
  • HY-149415
    Multi-kinase-IN-5
    		Inhibitor
    Multi-kinase-IN-5 (compound 15c) is a promising multi-kinase inhibitory agent. Multi-kinase-IN-5 inhibits a panel of protein kinases (RET, KIT, cMet, VEGFR1,2, FGFR1, PDGFR and BRAF), showing % inhibition of 74%, 31%, 62%, 40%, 73%, 74%, 59%, and 69%, respectively, and IC50 of 1.287, 0.117 and 1.185 μM against FGFR1, VEGFR, and RET kinases, respectively.
    Multi-kinase-IN-5
  • HY-143545
    RET-IN-8
    		Inhibitor
    RET-IN-8 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer.
    RET-IN-8
  • HY-E70781
    RET Y806H Recombinant Human Active Protein Kinase
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET Y806H is a mutant of RET. RET Y806H Recombinant Human Active Protein Kinase is a recombinant RET Y806H protein that can be used to study RET Y806H-related functions.
    RET Y806H Recombinant Human Active Protein Kinase
  • HY-176885A
    CDD-2212
    		Inhibitor
    CDD-2212 is a STK33 inhibitor, with a Kd of 1.9 nM and an IC50 of 999 nM. CDD-2212 has relatively weak inhibitory effects on off-target kinases, with IC50 values of 3223 nM for CLK1, 1555 nM for CLK2, 5884 nM for CLK4, and 1093 nM for RET. CDD-2212 can be used for the study of contraception.
    CDD-2212
  • HY-114588
    Tafetinib analogue 1
    		Inhibitor
    Tafetinib (SIM010603) analogue 1 is an analog of the tyrosine kinase receptor inhibitor Tafetinib (SIM010603)..
    Tafetinib analogue 1
  • HY-14979
    ML786
    		Inhibitor
    ML786 is a potent and orally bioavailable Raf inhibitor, with IC50s of 2.1, 4.2, and 2.5 nM for V600EΔB-Raf, wt B-Raf, and C-Raf, respectively. ML786 also inhibits Abl-1, DDR2, EPHA2, KDR, and RET (IC50=<0.5, 7.0, 11, 6.2, 0.8 nM). ML786 can be used for the research of cancers.
    ML786
  • HY-178964
    PROTAC RET Degrader 1
    		Degrader
    PROTAC RET Degrader 1 (Compound 20) is an orally active and blood-brain barrier-crossing RET PROTAC degrader with DC50 values for RET (WT), RET (G810S), RET (G810C), and RET (G810R) of 1.7, 3, 12, and 21 nM, respectively. PROTAC RET Degrader 1 exhibits potent anti-proliferative activity in cancer cell lines carrying oncogenic RET fusions (such as KIF5B-RET, CCDC6-RET) or mutations (such as RET (C634W)). PROTAC RET Degrader 1 shows significant anti-tumor activity in human tumor xenograft (PDX) mouse models. PROTAC RET Degrader 1 can be used for the study of RET-positive cancers Pink: RET ligand (HY-179308); Blue: CRBN ligand (HY-179307); Black: Linker).
    PROTAC RET Degrader 1
  • HY-174245
    RET-IN-30
    		Inhibitor
    RET-IN-30 (Compound 28) is a RET inhibitor that exhibits inhibitory activity against both wild-type RET and some of its mutants. RET-IN-30 can inhibit the proliferation of A549 cells and has anti-tumor activity.
    RET-IN-30
  • HY-174993
    FHND5071 (1H)
    		Inhibitor
    FHND5071 (1H) is a selective inhibitor targeting the RET (rearrangement during transfection) tyrosine kinase. FHND5071 (1H) is promising for research of RET-driven cancers (such as thyroid cancer, lung cancer, etc.).
    FHND5071 (1H)
  • HY-170373
    RET ligand-1
    		Inhibitor
    RET ligand-1 is a target protein ligand targeting RET that can be used to synthesize PROTAC LDD39 (HY-159967).
    RET ligand-1
  • HY-145023
    RET-IN-5
    		Inhibitor
    RET-IN-5 is a potent RET (rearranged during transfection) inhibitor with an IC50s of 0.4 nM and 135.1 nM for RET and VEGFR2, respectively (WO2021213476A1, compound 18).
    RET-IN-5